SBC Medical Group Holdings (SBC) Company Report

SBC Medical-supported Medical Corporation Nasukai has formed a strategic business alliance with Daibi Medical Aesthetics in Shanghai, China, aiming to enhance the Shonan Beauty Clinic brand recognition in China and support growth in inbound medical demand to Japan.
This alliance will involve sharing Nasukai's clinical expertise and operational know-how to improve services at Daibi Medical Aesthetics, while also deepening SBC Medical's understanding of China's medical environment and exploring long-term revenue opportunities from cross-border medical demand.
Inbound customer visits to Shonan Beauty Clinic have shown significant growth, nearly tripling from approximately 600 customers in early 2024 to around 1,700 customers by the end of 2025.
SBC Medical Group Holdings was listed on Nasdaq in September 2024 and subsequently included in the Russell 3000® Index in June 2025.

5 days ago

Press Release

SBC Medical Group Holdings Discusses Q3 2025 Performance and Global Expansion Strategy

SBC

M&A

New Projects/Investments

Guidance Update

SBC Medical Group Holdings (SBC), the largest aesthetic medical group in Japan, reported that its Q3 2025 sales are showing signs of bottoming out, with operating and net income turning around due to declining listing-related costs. The company maintains a sound financial base and plans for 2026 to be a "growth year" after 2025's restructuring.
SBC has initiated its global expansion strategy with a minority investment deal in Orange Twist, a U.S.-based med spa. The company aims for international operations, currently at 1% of revenue, to increase to 20% plus in the next three to five years, focusing on the U.S. and Southeast Asia.
The company's franchise clinics in Japan have expanded to 258 locations serving approximately 6.5 million annual customers, diversifying into orthopedics, ophthalmology, hair loss, and infertility treatments. SBC targets a 10%-50% growth rate for clinic count in the next 12-24 months, including M&A.

Jan 22, 2026, 9:25 PM

Transcript

SBC Medical Group Holdings Reports Q3 2025 Turnaround and Outlines Global Expansion Strategy

SBC

M&A

New Projects/Investments

Revenue Acceleration/Inflection

SBC Medical Group Holdings reported that Q3 2025 sales are showing signs of bottoming out, with operating income and net income turning around due to reduced listing-related costs.
The company has initiated its global expansion strategy with a minority investment in OrangeTwist, a U.S.-based med spa, aiming to leverage its expertise in the growing $71 billion U.S. aesthetic market by 2033.
SBC targets a substantial increase in international revenue from the current 1% to over 20% within the next three to five years, primarily driven by global M&A and partnerships.
The company projects a 10% to 50% growth in clinic count and overall revenue growth rates in the next 12-24 months, with 2026 anticipated as a growth year.

Jan 22, 2026, 9:25 PM

Transcript

SBC Medical Group Holdings Discusses Q3 2025 Performance and Global Expansion Strategy

SBC

New Projects/Investments

M&A

Guidance Update

SBC Medical Group Holdings, the largest aesthetic medical group in Japan, reported that its Q3 2025 sales are showing signs of bottoming out after declines due to business restructuring and franchise fee revisions, with operating income and net income turning around.
The company is actively pursuing global expansion, having recently made a minority investment in OrangeTwist, a US-based med spa, to establish its presence in the US market.
SBC aims to become the top medical group globally by 2050, with a target to increase international revenue from its current 1% to over 20% of total revenue within the next three to five years, focusing on partnerships and M&A in the US and Southeast Asia.
The company projects a 10%-50% growth rate for clinic locations over the next 12-24 months, including M&A, and expects to return to historical revenue growth rates of 10%-15%.

Jan 22, 2026, 9:25 PM

Transcript

SBC Medical Group Discusses Q3 2025 Performance, Global Expansion, and M&A Strategy

SBC

New Projects/Investments

M&A

Revenue Acceleration/Inflection

SBC Medical Group reported that its Q3 2025 sales are showing signs of bottoming out, with operating income and net income turning around due to declining listing-related costs. The company maintains a sound financial base and plans to deploy liquidity for strategic investments, including M&A.
The company is pursuing an incremental global expansion strategy, notably through a partnership and investment in OrangeTwist, a U.S.-based med spa with 24 clinics across several states. This strategy also targets Southeast Asia and involves potential small M&A.
SBC aims to be the leading medical group globally by 2050. M&A activities will continue to focus primarily on the Japanese market in both aesthetic and general medical areas, while global M&A will involve partnerships and smaller acquisitions to build market knowledge.
The Japanese aesthetic medicine market remains competitive but is showing signs of improvement, with the average revenue per customer visit recovering.

Jan 21, 2026, 9:00 PM

Transcript

SBC Medical Group Reports Q3 2025 Financial Turnaround and Details Global Expansion Strategy

SBC

New Projects/Investments

M&A

Guidance Update

SBC Medical Group, the largest aesthetic medical group in Japan, reported that its Q3 2025 sales are showing signs of bottoming out, and operating and net income are turning around due to declining listing-related costs.
The company's franchise clinics have expanded to 258 locations with approximately 6.5 million annual customers, and the average revenue per customer visit is recovering.
SBC is pursuing a global expansion strategy, including a recent investment in OrangeTwist, a U.S.-based med spa with 24 clinics across several states.
The long-term goal is to become the medical group chosen by the most customers in Japan by 2035 and globally by 2050, with an incremental approach to overseas growth.
M&A activities will continue, primarily in Japan for aesthetic and general medical areas, with consideration for opportunities in Southeast Asia and the U.S..

Jan 21, 2026, 9:00 PM

Transcript

SBC Medical Group Reports Q3 2025 Financial Turnaround and Details Global Expansion Strategy

SBC

New Projects/Investments

M&A

Revenue Acceleration/Inflection

SBC Medical Group, the largest aesthetic medical group in Japan, reported that its sales for Q3 2025 are showing signs of bottoming out, with operating income and net income turning around due to reduced listing-related costs. The company maintains a sound financial base and plans strategic investments.
The company operates 258 locations in Japan, serving approximately 6.5 million annual customers, and is diversifying its services to include orthopedics, ophthalmology, hair loss, and infertility treatment. The average revenue per customer visit is recovering.
SBC is pursuing an incremental global expansion strategy, aiming to become a leading global medical group by 2050. A key part of this strategy is a partnership with OrangeTwist, a U.S.-based med spa with 24 clinics across several states, leveraging SBC's scale and expertise in non-invasive treatments.
The company plans to continue M&A primarily in Japan, focusing on both aesthetic and general medical areas, while also considering minority investments and small M&A in Southeast Asia and the U.S. to support its global growth.

Jan 21, 2026, 9:00 PM

Transcript

SBC Medical Group Holdings Announces Strategic Investment and Partnership with OrangeTwist

SBC

New Projects/Investments

M&A

Revenue Acceleration/Inflection

SBC Medical Group Holdings has completed a strategic minority investment and established a collaboration framework with OrangeTwist, a leading U.S. medical spa chain.
This move marks SBC Medical's official entry into the United States, a key global market for aesthetic medicine, and represents a significant milestone in the company's global expansion strategy.
OrangeTwist, founded in 2015, specializes in non-invasive aesthetic treatments and currently operates 24 centers across six U.S. states.
The investment is the first step in SBC Medical's multi-year strategic plan to establish a leadership position in the U.S. medical aesthetics and wellness market, with a three-phase global expansion roadmap aiming for leadership from 2029 onwards.

Jan 6, 2026, 4:59 AM

Press Release

SBC Medical Group Holdings Announces Strategic Investment in OrangeTwist for US Market Entry

SBC

New Projects/Investments

M&A

SBC Medical Group Holdings has completed a strategic minority equity investment and established a formal collaboration with OrangeTwist, a leading US-based MedSpa network.
This transaction signifies SBC Medical's formal entry into the United States market, which is a strategic global market for medical aesthetics.
OrangeTwist, founded in 2015, currently operates 24 units across six US states, specializing in non-invasive aesthetic treatments.
This investment represents the first phase of SBC Medical's multi-year global expansion plan, with a roadmap targeting Entry (2025–2026), Scale (2027–2028), and Leadership (2029 onwards) in the US market.

Jan 6, 2026, 4:49 AM

Press Release

SBC Medical Announces Strategic Investment and Alliance with OrangeTwist

SBC

New Projects/Investments

M&A

SBC Medical Group Holdings Incorporated has completed a strategic minority investment and established a collaboration framework with OrangeTwist, a leading US-based MedSpa chain.
This transaction marks SBC Medical's official entry into the United States, a crucial global market for medical aesthetics, and represents a significant step in its global expansion strategy.
The partnership aims to leverage cross-border synergies between the US and Asia to foster long-term growth opportunities.
This investment is the first step in a multi-year plan for SBC Medical to establish a leading position in the US medical aesthetics and wellness market, initiating Phase 1 (2025-2026) of its global expansion roadmap.